G2 Gbio
Price chart
- MA5
- MA20
- MA60
Adjusted prices rescale past bars with coefficients taken from the base prices the exchange itself published, correcting for corporate actions such as stock splits and reverse splits. Cash dividends are not reflected, and the risk measures on this page never use these adjusted figures.
Each day's close multiplied by the listed share count of this share class alone, sampled weekly. It is the figure for this issue only, not a combined total across common and preferred shares.
Overview
Summary
G2 Gbio is a company established on March 22, 2017. It is listed on the KOSDAQ market.
The company operates as a drug delivery system platform provider using its InnoLAMP microsphere technology. It develops long-acting pharmaceuticals for diabetes, obesity, dementia, and post-surgical pain. The company provides licensing, joint development, and CDO/CDMO services to global pharmaceutical firms.
Business overview as filed
당사는 약효지속성 의약품 미립구 기술 분야의 선도 기업으로서 반감기 연장 의약품의 개발 수요에 부합하는 차세대 미립구 원천 기술과 글로벌 수준의 대량생산 공정 시설을 갖추고 있습니다. 당사의 기술은 합성 의약품, 펩타이드 의약품, 항체 의약품, RNA 치료제 등 다양한 소재의 약물을 탑재할 수 있는 범용성 높은 플랫폼 기술이기 때문에, 시장 내 다수 글로벌 제약사와 라이센싱, 공동개발 등 기술사업화 성과를 확보할 수 있을 뿐만 아니라, 당사의 기술은 CDO / CDMO 사업 또한 가능합니다.
당사의 약효지속성 의약품 개발을 위한 미립구 원천기술 “InnoLAMP (Innovative Long-Acting Microsphere Platform)”는 10~100 마이크로미터 크기의 미립구에 약물을 탑재하여 피하 또는 근육주사 시 체내에 미립구가 분해되면서 약효물질이 서서히 방출되도록 설계되며, 약물 종류에 따라 약효 지속시간을 수 일에서 수개월까지 유연하게 조절할 수 있습니다. 특히, 고함량 약물의 안정적 탑재, 약물의 생체이용률 향상, 주사부위 부작용 감소, 균일한 미립구의 대량생산 및 고분자 제조 비용 절감 등을 실현하여, 기존 상용 기술 대비 차별화에 성공하였습니다.
주력 파이프라인으로는 GB-7001 (1개월 약효 지속 당뇨/비만 치료제), GB-5001 (1개월 약효 지속 치매 치료제), GB-6002 (3일 이상 약효 지속 수술 후 통증 치료제)가 있으며, 당사는 다수의 임상 시험 (프로그램)을 통해 효능 및 약동학 프로파일의 우수성을 검증하였습니다.
당사의 원천 기술과 대량 생산 공정은 미국, 유럽, 중국, 일본 등 주요 의약품 시장에서 특허 등록이 완료되었으며, 더 나아가 주요 파이프라인의 조성물 특허까지 확보되어 높은 진입장벽을 구축하였습니다. 특히 경쟁 미립구 제조기술 대비 생산공정이 단순하면서도 높은 품질 안정성과 국내 유일하게 대량생산이 가능한 점 등 기술력과 상업 생산 능력을 인정받아 다수의 국내외 제약사로부터 여러 유형의 사업 협력을 수행하고 있습니다. 또한, CDMO 및 기술이전 활동을 더욱 확대하여 기술사업화를 통한 고부가가치 창출을 본격화할 계획입니다.
Company overview
(1) 연결대상 종속회사 개황- 연결대상 종속회사 현황(요약)
- 연결대상회사의 변동내용
기업공시서류 작성기준일 현재 당사는 해당사항 없습니다.
(2) 회사의 법적ㆍ상업적 명칭
당사의 명칭은 “주식회사 지투지바이오”라고 표기합니다. 또한 영문으로는 G2GBIO, Inc. 라 표기합니다.
(3) 설립일자 및 존속기간
당사는 약효지속성의약품 연구 및 개발을 목적으로 2017년 3월 22일에 설립되었습니다.
(4) 본사의 주소, 전화번호, 홈페이지 주소
(5) 중소기업 등 해당 여부
(6) 주요 사업의 내용
당사는 약효지속성 의약품 개발을 위한 미립구 원천기술(InnoLAMP)을 보유한 DDS(Drug Delivery System, 약물전달시스템) 플랫폼 기업입니다. 반감기 연장 의약품의 개발 수요에 부합하는 차세대 미립구 원천기술과 글로벌 수준의 대량 생산 공정 및 시설을 갖추고 있습니다. 당사의 기술은 합성 의약품, 펩타이드 의약품, 항체 의약품, RNA 치료제 등 다양한 소재의 약물을 탑재할 수 있는 범용성 높은 풀랫폼 기술이기 때문에, 시장 내 다수 글로벌 제약사와 라이센싱, 공동개발 등 기술사업화 성과를 확보할 수 있을 뿐만 아니라, CDO/CDMO사업 또한 본격화하고 있습니다.
(7) 회사의 주권상장(또는 등록ㆍ지정) 및 특례상장에 관한 사항
Transcribed verbatim from the sentences the filer wrote in the fiscal 2025 business report (received 2026.03.18), tables and figures omitted.
- The summary is written separately from the filed text and is not the filer's wording, so it may phrase things differently from or omit parts of the original, which is shown alongside for checking.
- The company introduction reproduces the sentences the filer wrote in its business report, with tables, figures and the sentences that point to other sections of the report omitted, and the accuracy of their content has not been separately verified.
The conditions for computing a value are not met over this window, which happens when the listing is short, turnover is thin, or halts are frequent.
Characteristic line
No window of this issue can carry a characteristic line yet.
Each point is one period's index excess return and issue excess return, and the line is the regression fitted to those points. The risk-free rate is the certificate of deposit rate.
- Beta summarizes by regression how far the issue's return moved together with the KOSPI200 or KOSDAQ150 index return, and the index is only a stand-in for the whole market.
- The intercept is the average excess return the index does not explain, and when the interval shown beside it contains zero it cannot be told apart from zero.
- Beta and the intercept are computed from the sample of the chosen window and frequency and are not values for the period ahead.
- At the daily frequency a beta corrected for differences in trading times is shown alongside, and the gap between the two shows how much later than the index the issue's trades are reflected.
Financials
| 2023 | 2024 | 2025 | TTM | |
|---|---|---|---|---|
| RevenueKRW 100M | 7 | 8 | 4 | 22 |
| Revenue growth% | — | 3.93 | -44.98 | — |
| Operating incomeKRW 100M | -131 | -108 | -122 | -126 |
| Net incomeKRW 100M | -105 | -833 | -121 | -176 |
| Attributable to owners | Not applicable | Not applicable | Not applicable | Not applicable |
| Attributable to minorities | Not applicable | Not applicable | Not applicable | Not applicable |
| Operating margin% | -1,776.67 | -1,399.80 | -2,884.22 | -568.74 |
| Net margin% | -1,417.41 | -10,827.32 | -2,857.07 | -793.67 |
| ROE | Not applicable | Not applicable | Not applicable | Not applicable |
| ROA% | -33.24 | -328.48 | -17.84 | -7.48 |
| Debt ratio% | -182.39 | -121.20 | 16.13 | 69.08 |
| Current ratio% | 24.12 | 7.58 | 735.29 | 237.61 |
| Quick ratio | Not applicable | Not applicable | Not applicable | Not applicable |
| Reserve ratio% | -5,907.14 | -16,434.93 | 591.92 | 1,346.08 |
| Free cash flowKRW 100M | -118 | -85 | -142 | — |
| FCF margin% | -1,588.63 | -1,111.34 | -3,364.24 | — |
| Capex to revenue% | 108.39 | 75.07 | 73.72 | — |
| Receivable daysdays | — | 191.2 | 524.5 | — |
| Payable daysdays | — | 720.9 | 897.0 | — |
| EPSKRW | -7,688 | -57,297 | -862 | — |
| PER | Not applicable | Not applicable | Not applicable | Not applicable |
| BPS | Not applicable | Not applicable | Not applicable | Not applicable |
| PBR | Not applicable | Not applicable | Not applicable | Not applicable |
| Dividend per share | Not applicable | Not applicable | Not applicable | Not applicable |
Separate basis
Profit flowKRW 100M
This fiscal year shows a loss at gross profit, operating income, profit before tax or net income, so it is left to the table rather than drawn as a flow.
This diagram traces where revenue goes at each step on its way to net income, using the filed amounts as they are. The non-operating result is taken as the difference between profit before tax and operating income and is shown as income or expense by its sign, and whatever a step's items leave unexplained is shown separately as other.
Revenue compositionKRW 100M
Margins%
Cash flow by activityKRW 100M
Balance sheet compositionKRW 100M
Debt ratio%
The left bar splits assets into current and non-current and the right bar splits the financing of those assets into liabilities and equity, so the two bars stand at the same height.
Quarterly resultsKRW 100M
Year-on-year growth%
Each quarterly bar is that quarter's three months and is never mixed with an annual figure. The growth rate is computed only where the same quarter a year earlier is also shown here, and is left blank when the base was a loss.
Cash conversion cycledays
Free cash flow breakdownKRW 100M
Inventory days and receivable days stack upward, payable days hang downward, and the cash conversion cycle they net to is drawn as the line. Each day count uses the average balance with the prior year, so the oldest year is not drawn. A day count whose line was not filed is left out, and the cycle is shown only for years that carry all three.
Free cash flow is cash from operating activities less spending on property, plant and equipment, and all three bars keep the sign as filed.
Owners' net margin%
Asset turnoverx
Financial leveragex
ROE%
ROE is the product of the owners' net margin, asset turnover and financial leverage. All three use period-end balances as denominators, and profit and equity are on the owners' basis, so the product matches the ROE in the table.
Financial statements
Balance sheet
| 2023 | 2024 | 2025 | |
|---|---|---|---|
| 315 | 253 | 677 | |
| 159 | 107 | 533 | |
| Cash and cash equivalentsKRW 100M | 116 | 100 | 80 |
| Short-term financial instrumentsKRW 100M | 30 | — | 371 |
| InventoriesKRW 100M | Not applicable | Not applicable | Not applicable |
| Trade and other receivablesKRW 100M | 6 | 2 | 10 |
| 156 | 146 | 144 | |
| Property, plant and equipmentKRW 100M | 148 | 137 | 128 |
| Intangible assetsKRW 100M | 3 | 3 | 4 |
| 698 | 1,449 | 94 | |
| 660 | 1,417 | 73 | |
| Trade and other payablesKRW 100M | 13 | 10 | 12 |
| Short-term borrowingsKRW 100M | 14 | 13 | 13 |
| Current lease liabilitiesKRW 100M | 3 | 3 | 3 |
| 39 | 32 | 22 | |
| Long-term borrowingsKRW 100M | 21 | 14 | 9 |
| Non-current lease liabilitiesKRW 100M | 9 | 9 | 7 |
| -383 | -1,195 | 583 | |
| Not applicable | Not applicable | Not applicable | |
| Issued capitalKRW 100M | 7 | 7 | 82 |
| Capital surplusKRW 100M | 43 | 66 | 1,898 |
| Retained earningsKRW 100M | -456 | -1,290 | -1,412 |
| Accumulated other comprehensive incomeKRW 100M | 4 | -1 | — |
| Other equityKRW 100M | 19 | 21 | 15 |
| Non-controlling interestsKRW 100M | Not applicable | Not applicable | Not applicable |
| 당기법인세자산As filed | 0 | 1 | 0 |
| 유동 당기손익-공정가치측정금융자산As filed | — | — | 71 |
| 기타유동자산As filed | 3 | 2 | 2 |
| 기타유동금융자산As filed | 4 | 2 | 0 |
| 순확정급여자산As filed | — | — | 1 |
| 기타비유동자산As filed | 4 | 5 | 7 |
| 장기금융상품As filed | — | — | 4 |
| 기타비유동금융자산As filed | 2 | 0 | 0 |
| 장기매출채권 및 기타비유동채권As filed | — | — | 0 |
| 자본과부채총계As filed | 315 | 253 | 677 |
| 파생상품부채As filed | 112 | 279 | — |
| 전환사채As filed | 64 | 78 | — |
| 상환전환우선주부채As filed | 411 | 990 | — |
| 유동성장기차입금As filed | 42 | 41 | 39 |
| 기타 유동부채As filed | 2 | 3 | 5 |
| 장기매입채무 및 기타비유동채무As filed | 4 | 4 | 4 |
| 확정급여채무As filed | 3 | 3 | — |
| 기타 비유동 부채As filed | 1 | 1 | 1 |
Income statement
| 2023 | 2024 | 2025 | |
|---|---|---|---|
| 7 | 8 | 4 | |
| Cost of salesKRW 100M | 4 | 6 | 5 |
| Gross profitKRW 100M | 3 | 2 | -0 |
| SG&A expensesKRW 100M | 27 | 33 | 41 |
| -131 | -108 | -122 | |
| Finance incomeKRW 100M | 37 | 5 | 8 |
| Finance costsKRW 100M | 12 | 729 | 7 |
| Other incomeKRW 100M | 1 | 0 | 0 |
| Other expensesKRW 100M | 0 | 1 | 0 |
| -105 | -833 | -121 | |
| Income tax expenseKRW 100M | Not applicable | Not applicable | Not applicable |
| -105 | -833 | -121 | |
| Attributable to ownersKRW 100M | Not applicable | Not applicable | Not applicable |
| Attributable to minoritiesKRW 100M | Not applicable | Not applicable | Not applicable |
| Basic earnings per shareKRW | -7,688 | -57,297* | -862 |
| Diluted earnings per shareKRW | -7,688 | -57,297* | -862 |
| -104 | -838 | -121 | |
| Other comprehensive incomeKRW 100M | 1 | -6 | -0 |
| 경상개발비As filed | 107 | 77 | 81 |
| 당기손익으로 재분류되지 않는 항목As filed | 1 | -6 | -0 |
| 기타포괄-공정가치금융부채평가손익As filed | 1 | -5 | 1 |
| 확정급여제도의 재측정손익(세후)As filed | -1 | -1 | — |
| 확정급여제도의재측정요소As filed | — | — | -1 |
Cash flow statement
| 2023 | 2024 | 2025 | |
|---|---|---|---|
| Net incomefrom the income statement | -105 | -833 | -121 |
| Total adjustments to operating cash flowcomputed | -5 | 753 | -18 |
| -110 | -80 | -139 | |
| Interest receivedKRW 100M | 0 | 4 | 2 |
| Interest paidKRW 100M | 8 | 5 | 5 |
| DepreciationKRW 100M | 17 | 18 | 15 |
| AmortisationKRW 100M | 0 | 1 | 1 |
| Income taxes paidKRW 100M | -0 | 1 | -0 |
| -40 | 21 | -451 | |
| Purchase of property, plant and equipmentKRW 100M | 8 | 6 | 3 |
| Proceeds from sale of property, plant and equipmentKRW 100M | Not applicable | Not applicable | Not applicable |
| Purchase of intangible assetsKRW 100M | 0 | 0 | 0 |
| 218 | 42 | 570 | |
| Issue of sharesKRW 100M | 14 | 7 | 578 |
| Cash at beginning of periodKRW 100M | 48 | 116 | 100 |
| 116 | 100 | 80 | |
| Effect of exchange rate changesKRW 100M | 0 | 1 | 0 |
| Net change in cash and cash equivalentsKRW 100M | 68 | -16 | -20 |
| 리스부채의 지급As filed | 2 | 1 | 2 |
| 전환사채의 증가As filed | 174 | — | — |
| 상환전환우선주부채의 증가As filed | 30 | 45 | — |
| 단기차입금의 상환As filed | 6 | 1 | — |
| 유동성장기차입금의 상환As filed | 4 | 9 | 7 |
| 장기차입금의 차입As filed | 6 | — | — |
| 단기차입금의 차입As filed | 6 | — | — |
| 장기선급금의 감소(증가)As filed | -2 | -3 | -3 |
| 임차보증금의 감소As filed | — | 0 | 0 |
| 임차보증금의 증가As filed | 0 | 0 | — |
| 단기금융상품의 처분As filed | — | 30 | — |
| 당기손익-공정가치금융자산의처분As filed | — | — | 24 |
| 단기금융상품의 취득As filed | 30 | — | 371 |
| 당기손익-공정가치측정금융자산의 취득As filed | — | — | 94 |
| 운전자본의 증감As filed | 2 | 2 | -39 |
| 장기금융상품의 취득As filed | — | — | 4 |
| 퇴직연금의 감소(증가)As filed | -2 | -4 | -9 |
| 미수금의 감소(증가)As filed | -0 | 1 | -1 |
| 매출채권의 감소(증가)As filed | 0 | 1 | -4 |
| 기타비유동부채의 증가(감소)As filed | 0 | 0 | 0 |
| 기타비유동자산의 감소(증가)As filed | — | — | 0 |
| 미지급금의 증가(감소)As filed | 3 | 1 | -0 |
| 퇴직급여의 지급As filed | — | -0 | -0 |
| 기타유동자산의 감소(증가)As filed | 1 | 2 | -27 |
| 계약부채의 증가(감소)As filed | -0 | -0 | -0 |
| 기타유동부채의 증가(감소)As filed | 0 | 1 | 2 |
| 수익비용의 가감As filed | 1 | 752 | 23 |
| 외화환산이익As filed | 0 | 1 | 0 |
| 유형자산처분이익As filed | 1 | — | 0 |
| 파생상품부채평가이익As filed | 2 | 0 | 2 |
| 이자비용As filed | 11 | 24 | 7 |
| 당기손익-공정가치금융자산처분이익As filed | — | — | 0 |
| 무형자산폐기손실As filed | — | 0 | — |
| 유형자산처분손실As filed | 0 | 0 | — |
| 당기손익-공정가치금융자산평가이익As filed | — | — | 1 |
| 파생상품부채평가손실As filed | — | 173 | — |
| 외화환산손실As filed | 0 | 0 | 0 |
| 퇴직급여As filed | 3 | 3 | 5 |
| 주식보상비용As filed | 7 | 6 | 4 |
| 당기손익-공정가치금융부채평가손실As filed | 0 | 532 | — |
| 당기손익-공정가치금융부채평가이익As filed | 34 | — | — |
| 이자수익As filed | 1 | 4 | 5 |
| 당기순이익(손실)As filed | -105 | -833 | -121 |
| 환율변동효과 반영전 현금및현금성자산의 순증가(감소)As filed | 68 | -17 | -20 |
In the latest fiscal year operations and investing consumed cash raised through financing activities.
A year whose own filing is absent is filled from the restated comparative in the following filing, and is marked as such. Operating indicators outside the statements, such as order backlogs, and audit opinions are not covered here, and per-share figures follow the filed values without retroactive adjustment for share splits.
Transcribed verbatim from the sentences the filer wrote in the fiscal {year} business report (received {date}), with tables, figures and cross-references to other sections omitted.
The newest annual filing shown was received on 2026.03.18.
Audit opinion
| Fiscal year | Opinion | Auditor | Fiscal year end |
|---|---|---|---|
| 2025 | 적정의견Term 9 | 신우회계법인 | 2025-12-31 |
| 2024 | 적정의견Term 8 | 삼덕회계법인 | 2025-12-31 |
| 2023 | 적정의견Term 7 | 삼덕회계법인 | 2025-12-31 |
The auditor's name and the opinion are transcribed verbatim from the filed audit report, and the wording follows the filer. A fiscal year shown twice means the filing carried two entries that the source does not distinguish.
Korean audit opinions come in four kinds, where an unqualified opinion (적정) finds the statements fairly presented, a qualified opinion (한정) does so except for a stated matter, an adverse opinion (부적정) finds them not fairly presented, and a disclaimer of opinion (의견거절) means the auditor could not obtain enough evidence to form a view.